Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Vivani Medical, Inc
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
76High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05670379CT.gov Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant | — | Completed | — | — | — |
NCT04307797CT.gov Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes | — | Completed | — | — | — |
NCT04520490CT.gov Brain Activation and Satiety in Children 2 | — | Active Not Recruiting | — | — | — |
NCT03671733CT.gov Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients | — | Unknown | — | — | — |
NCT03419624CT.gov The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients | — | Terminated | — | — | — |
NCT03352869CT.gov Research of Exenatide for Overweight/Obese PCOS Patients With IGR | — | Completed | — | — | — |
NCT03361098CT.gov DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 | — | Completed | — | — | — |
NCT03151005CT.gov The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS | — | Completed | — | — | — |
NCT02635386CT.gov EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | — | Completed | — | — | — |
NCT02794402CT.gov Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI | — | Completed | — | — | — |
Show 17 more trialsShow fewer
NCT02690987CT.gov Gut Hormones in Obesity, Nicotine and Alcohol Dependence | — | Unknown | — | — | — |
NCT02313220CT.gov Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight | — | Completed | — | — | — |
NCT02118376CT.gov Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status | — | Unknown | — | — | — |
NCT02160990CT.gov Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying | — | Completed | — | — | — |
NCT02170324CT.gov GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men | — | Completed | — | — | — |
NCT02104739CT.gov Effects of Antidiabetic Medications on the Postprandial State in Prediabetes | — | Completed | — | — | — |
NCT01857895CT.gov Feasibility Study of Exenatide by Continuous Subcutaneous Infusion | — | Completed | — | — | — |
NCT01794429CT.gov Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue | — | Completed | — | — | — |
NCT01484873CT.gov Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor | — | Completed | — | — | — |
NCT01590433CT.gov Weight Loss With Exenatide Treatment | — | Completed | — | — | — |
NCT01501084CT.gov Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women | — | Completed | — | — | — |
NCT01281228CT.gov The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes | — | Completed | — | — | — |
NCT01237197CT.gov Exenatide in Extreme Pediatric Obesity | — | Completed | — | — | — |
NCT00856609CT.gov The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects | — | Completed | — | — | — |
NCT00845559CT.gov The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults | — | Withdrawn | — | — | — |
NCT00500370CT.gov A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients | — | Completed | — | — | — |
NCT00456885CT.gov The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Exenatide (this asset) | Vivani Medical, Inc | Approved | BB · 69 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Exenatide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Type 2 Diabetes Mellitus | — | P4 | BBB · 78 |
| Prediabetes Syndrome | — | P4 | BBB · 76 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Exenatide in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/exenatide-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →